drugset / Trial / NCT06846528

A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants

NCT06846528

Phase 1 Completed 16 enrolled AstraZeneca Parexel · collab
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to assess the pharmacokinetics (PK) of AZD2389 when administered alone and in combination with itraconazole in healthy participants.

Timeline

Start
2025-02-26
Primary completion
2025-04-23
Completion
2025-04-23

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2389 Small molecule Oral
Subject Itraconazole Small molecule Oral

Indications

No indication recorded.